Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | MPC2 | O95563 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559726 | 0.89 | PPARG (0.49) | PPARGFFAR1 | |
| SCHEMBL19217570 | 0.89 | PPARG (0.68) | PPARGFFAR1AOC3MPC2CYP2C8 | |
| SCHEMBL19559659 | 0.86 | PPARG (0.41) | PPARGFFAR1HSD17B3GAAMPC2 | |
| SCHEMBL19559693 | 0.86 | PPARG (0.41) | PPARGFFAR1HSD17B3GAAMPC2 | |
| SCHEMBL19217776 | 0.82 | PPARG (0.52) | PPARGFFAR1CYP2C9 | |
| SCHEMBL19559756 | 0.82 | PPARG (0.52) | PPARGFFAR1CYP2C9 | |
| SCHEMBL19559762 | 0.81 | PPARG (0.45) | PPARGFFAR1HSD17B3MPC2CYP2C8 | |
| SCHEMBL19559741 | 0.80 | PPARG (0.37) | PPARGFFAR1HSD17B3GAAMPC2 | |
| SCHEMBL19217761 | 0.80 | PPARG (0.68) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL19559661 | 0.80 | PPARG (0.53) | PPARGGAAMPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |